For patients with well differentiated NET whose carcinoid symptoms are controlled on SSAs but have persistently elevated 5HIAA, would you consider adding telotristat for prevention of carcinoid heart disease?

I do not think routinely adding therapies to treat biochemical parameters is appropriate.

As many are likely aware, the tryptophan hydroxylase inhibitor telotristat was approved for the treatment of carcinoid syndrome diarrhea based on the TELESTAR study, which demonstrated a statistically significan...